CD Biosynsis offers accelerated HeLa Cells Strain Development and Screening Services, combining advanced genome editing with high-throughput automation to create optimized, monoclonal cell lines for biomedical research. HeLa cells, being the first and most widely used human immortalized cell line, serve as the foundational chassis for cancer research, virology, and drug discovery. Our services leverage precision engineering (CRISPR-Cas9, Base Editing) to overcome the challenges of the complex HeLa hyper-triploid genome, enabling the systematic development of strains with enhanced reporter stability, specific metabolic phenotypes, or viral susceptibility. We couple this with automated High-Throughput Screening (HTS) technologies to rapidly isolate and verify high-performing clones, providing a fast track to verified research-grade cell banks.
Get a QuoteStrain development in HeLa cells focuses on transforming a variable cancer line into a high-fidelity, reproducible research tool. Our integrated platform significantly accelerates the development cycle by utilizing multiplex genome editing to target multiple alleles simultaneously, ensuring complete functional outcomes in an aneuploid host. We employ automated single-cell isolation and miniaturized culture systems to evaluate thousands of variants for phenotypic consistency, growth kinetics, and reporter intensity. This data-driven approach dramatically reduces the timeline for establishing stable, well-characterized cell lines required for large-scale screening campaigns or long-term mechanistic studies.
Multi-Allelic CRISPR (KO/KI)
Specialized RNP delivery protocols designed to achieve simultaneous disruption or integration across all copies of a target gene in the hyper-triploid HeLa genome.
Base & Prime Editing
Introduction of precise point mutations or small insertions without double-strand breaks, ideal for creating isogenic disease models with specific cancer-relevant SNPs.
Lentiviral Transduction
Used for stable, high-copy integration of complex transgene cassettes or shRNA/CRISPRi components for sustained gene repression.
FACS & Image-Based Isolation
Automated fluorescence-activated cell sorting or high-speed imaging to identify and deposit single cells based on viability and reporter expression levels.
Miniaturized Bioassays
Quantitative measurement of phenotypic outputs—such as drug sensitivity, viral entry, or luciferase activity—in 96/384-well microplate formats.
Genomic Verification HTS
Rapid, high-throughput sequencing (HTS) or junction PCR to verify the precise genotype of thousands of monoclonal candidates in parallel.
Reporter System Assembly
Site-specific knock-in of fluorescent or bioluminescent reporters under native or safe-harbor promoters for real-time signaling analysis.
Metabolic & Fitness Tuning
Engineering cells for improved growth in serum-free media, reduced apoptosis, or optimized metabolic profiles for viral vector production.
Host Factor Engineering
Knockout of endogenous receptors or host restriction factors to create specialized strains for infectious disease research.
An integrated, iterative pipeline designed for rapid monoclonal strain optimization.
1. Rational Design & Genetic Build
2. High-Throughput Monoclonal Isolation
3. Phenotypic & Genomic Screening
4. Scale-up & Characterization
Establish the target profile and design CRISPR/Base-editing tools. Synthesize gRNAs and donor templates for precise multi-allelic modification.
Perform multiplex delivery into HeLa cells via optimized transfection or electroporation.
Establish a bulk edited population and utilize FACS or automated liquid handling to deposit single cells into microplates.
Expand monoclonal colonies under optimized growth conditions to ensure maximal viability and recovery rates.
Expand lead clones in larger vessel formats to confirm stability post-thaw and across multiple passages.
Final characterization including karyotyping, Mycoplasma testing, and full phenotypic profiling.
Delivery of cryopreserved research-grade cell banks and comprehensive development reports.
Aneuploidy Mastery
Expertise in achieving complete functional knockouts or homozygous knock-ins despite the extra chromosome copies inherent in the HeLa genome.
Automated Precision
Integration of HTS and automated cloning ensures the isolation of the rare, ideal clone with perfectly balanced growth and reporter expression.
Long-term Stability
Focus on site-specific integration into verified genomic safe harbors prevents the gene silencing common in human cancer lines.
Customized Phenotypes
Ability to tailor strains for specific industrial or research environments, including serum-free adaptation or viral resistance.
1. How does aneuploidy affect HeLa strain development?
HeLa cells typically have three or more copies of many chromosomes. This requires highly efficient CRISPR/RNP delivery and thorough HTS-based genotyping to ensure every allele is correctly modified, preventing residual "wild-type" activity.
2. What types of reporters can be screened for?
We screen for fluorescent reporters (GFP, mCherry), luminescent proteins (Luciferase), and cell-surface markers via FACS. We also perform image-based screening for sub-cellular protein localization.
3. Can you adapt HeLa strains for serum-free suspension growth?
Yes. As part of our strain development, we can perform metabolic engineering and sequential adaptive screening to transition adherent HeLa strains into high-density suspension cultures.
4. How do you ensure the genetic stability of the developed strain?
By using CRISPR/HDR to integrate cassettes into stable genomic safe harbors and performing stability testing over 30-50 passages, ensuring consistent phenotype and transgene expression.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.